Please upgrade your browser.
Designed to thwart blood vessel growth in tumors
The worldwide effort to find cures for rare disease is often the work of small organizations such as the the Myrovlytis Trust, a not-for-profit organization in Great Britain dedicated to finding treatments and cures for rare diseases. John Solly, charity manager for the Myrovlytis Trust, talks with host Dr. Bruce Bloom, the rationale for focusing large dollars on diseases affecting a small population and how the Trust is approaching the search for a cure to their first target disease, Birt-Hogg-Dubé Syndrome.
The American Cancer Society, which has long been a staunch defender of most cancer screening, is now saying that the benefits of detecting many cancers, especially breast and prostate, have been overstated.
Metastatic renal cell carcinoma (RCC) has poor outcomes. Metastatic disease is resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Although targeted cancer therapies have improved progression-free survival for RCC they have not yet demonstrated much improvement in overall survival. What next after failure of these drugs?
Exercise can reduce the often debilitating fatigue that cancer patients experience during chemotherapy, new research shows.
In a New York Times Magazine article, Peter Singer asks: "You have advanced kidney cancer. It will kill you, probably in the next year or two. A drug called Sutent slows the spread of the cancer and may give you an extra six months, but at a cost of $54,000. Is a few more months worth that much?" See original New York Times Magazine article: http://tinyurl.com/lb5ek2
Download the National Cancer, Institute Division of Extramural Activities, Annual Report 2008 (in PDF format).
|Powered by NeonCRM|